This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
=== Phase 2 === AD-036 – undefined mechanism of action [6] Atomoxetine/mineralocorticoid receptor antagonist (atomoxetine/antimineralocorticoid; AD-113) – combination of atomoxetine (norepinephrine reuptake inhibitor) and a mineralocorticoid receptor antagonist [7] Atomoxetine/trazodone (trazodone/atomoxetine; AD-504) – combination of atomoxetine (norepinephrine reuptake inhibitor) and trazodone (various actions/hypnotic) [8] BAY-2586116 – potassium channel blocker [9] CX-1739 – ampakine (AMPA receptor positive allosteric modulator) [10] Dronabinol low-dose (tetrahydrocannabinol; THC; PP-001) – cannabinoid CB1 and CB2 receptor agonist [11] Dronabinol/palmidrol (SCI-110; THX-OSA01; THX-RS01; THX-110; THX-TS01; THC/PEA) – combination of dronabinol (THC; cannabinoid receptor agonist) and palmidrol (palmitoylethanolamine (PEA); various actions) [12] Lorundrostat (MLS-101; MT-4129) – aldosterone synthase (CYP11B2) inhibitor [13] Phentermine/topiramate (Qnexa; Qsiva; Qsymia; topiramate/phentermine; VI-0521) – combination of phentermine (norepinephrine releasing agent) and topiramate (various actions) [14] Research programme: Sleep disordered breathing therapeutics - Shinogi-Apnimed Sleep Science – undefined mechanisms of action [15] SASS-001 – purinergic P2X3 receptor antagonist [16] Sivopixant (S-600918) – purinergic P2X3 receptor antagonist [17] Sulthiame (SASS-002; sulthiame; Sultia; sultiame) – carbonic anhydrase inhibitor [18] [19] Trazodone/viloxazine (AD-816; viloxazine/trazodone) – combination of trazodone (various actions/hypnotic) and viloxazine (norepinephrine reuptake inhibitor) [20]
In August 2008, Svante Cornell, Johanna Popjanevski and Niklas Nilsson from the Swedish Institute for Security and Development Policy commented that preceding the war, "Moscow's increasingly blatant provocations against Georgia led to a growing fear in the analytic community that it was seeking a military confrontation," adding "Russia had been meticulously preparing an invasion of Georgia through the substantial massing and preparation of forces in the country's immediate vicinity." The paper pointed out that its assertions were "initial conclusions," and because of "the recent nature of the events, however, it is possible that some information reflected here will need correction as more solid evidence emerges."
Validation activities are conducted to ensure that the resulting products and services meet the requirements for the specified application or intended use. Verification activities are conducted to ensure that the design and development outputs meet the input requirements. It also notes that verification and validation have distinct purposes but can be conducted separately or in any combination, as is suitable for the products and services of the organization. The National Institute of Standards and Technology Information Technology Laboratory Computer Security Resource Center has a variety of definitions for both validation and verification
Sources: en.wikipedia.org
==== Sen-chan ==== Senichi Enari (江成 仙一, Enari Sen'ichi), also known as "Sen-chan" (センちゃん), is the eccentric, yet calmest and smartest member, of the team, due in part to his ability to think things through and being able to do his best thinking while in a handstand, which he considers his "thinking pose". Sen-chan serves as Deka Green (デカグリーン, Deka Gurīn). The oldest of seven siblings from a poor family, he displays nycto- and claustrophobia after accidentally falling into a well when he was a child. He was subsequently rescued by a policeman, which inspired him to take up police work. Despite his usually calm demeanor, he is said to be scary when angered. He also displays a crush on his teammate Umeko, but avoids showing it publicly. As of the crossover film Mahō Sentai Magiranger vs. Dekaranger, they have moved in together. As Deka Green, Sen-chan wields the D-Knuckle and D-Rod, which can combine to form the D-Blaster (ディーブラスター, Dī Burasutā) rifle. He also shares riding the Machine Bull (マシンブル, Mashin Buru) police car with Umeko. Using the D-Rod, Sen-chan can perform the Green Crash (グリーンクラッシュ, Gurīn Kurasshu) attack. Sen-chan is portrayed by Yousuke Itou (伊藤 陽佑, Itō Yōsuke). As a child, he is portrayed by Kengo Tajima (田島 健吾, Tajima Kengo).
=== Obesity === Liraglutide may also be used together with diet and exercise for chronic weight management in adults. Liraglutide led to greater weight loss than some previous glucagon-like peptide analogues, but is less effective than the standard weight loss dose of semaglutide.
This was followed in 1947 by the widespread introduction of methadone, another structurally unrelated compound with pharmacological properties similar to those of morphine. After World War I, further advances were made in the field of intratracheal anesthesia. Among these were those made by Sir Ivan Whiteside Magill (1888–1986). Working at the Queen's Hospital for Facial and Jaw Injuries in Sidcup with plastic surgeon Sir Harold Gillies (1882–1960) and anesthetist E. Stanley Rowbotham (1890–1979), Magill developed the technique of awake blind nasotracheal intubation. Magill devised a new type of angulated forceps (the Magill forceps) that are still used today to facilitate nasotracheal intubation in a manner that is little changed from Magill's original technique. Other devices invented by Magill include the Magill laryngoscope blade, as well as several apparatuses for the administration of volatile anesthetic agents. The Magill curve of an endotracheal tube is also named for Magill. The first hospital anesthesia department was established at the Massachusetts General Hospital in 1936, under the leadership of Henry K. Beecher (1904–1976). Beecher, who received his training in surgery, had no previous experience in anesthesia. Although initially used to reduce the sequelae of spasticity associated with electroconvulsive therapy for psychiatric disease, curare found use in the operating rooms at Bellvue by E.M. Papper and Stuart Cullen in the 1940s using preparations made by Squibb.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.